Hello. It's July 12.

What does it take to live to 100?

Scientists just got a lot closer to an answer. They analyzed the blood of some of the world's longest-lived people - and found something surprisingly consistent about what their metabolisms look like at the molecular level.

Meanwhile, the biggest Alzheimer's drug data event of the year opens today in London. And the GLP-1 longevity debate is getting heated.

Let's get into it.

The rundown for this week:

Let's get to it. 👇

Low vitamin C in the blood is linked to less gray matter in the brain - a study of 2,000+ older adults in Japan found that people with lower vitamin C levels had measurably less gray matter (the brain tissue responsible for processing, memory, and movement). The link between this basic vitamin and brain structure is stronger than most people expect. ScienceDaily

Repair Bio just received an FDA designation for its atherosclerotic plaque regression program - most cardiovascular drugs slow plaque buildup. Repair Bio is trying to actually reverse it - shrinking the arterial deposits that drive heart attacks and strokes. An FDA designation signals the agency takes the science seriously. Longevity.Technology

Scientists discovered a protein called "Mitch" that simultaneously burns fat and blocks new fat cells from forming - when disabled in human cells, it boosts fat burning, increases energy use, and prevents fat cell formation. It points to a potential obesity treatment that works through a completely different mechanism than GLP-1 drugs. ScienceDaily

LyGenesis won a research award to advance its cell therapy approach for type 1 diabetes - the company regrows functional pancreatic tissue using the lymph nodes as a bioreactor. If it works at scale, this isn't just a diabetes breakthrough - it's a broader proof of concept for organ regeneration through the lymphatic system. Longevity.Technology

A Yale study of nearly 4,000 adults found that 45% of people over 65 improved in at least one health area over three years - and mindset was the strongest predictor - cognitive improvement in 32%, physical in 28%. The biggest predictor wasn't a drug, a supplement, or an exercise protocol. It was how positively someone viewed their own aging. SUCCESS / Yale / Geriatrics

If you want to know what extreme longevity looks like biologically, stop asking what centenarians eat. Start asking what their blood actually contains.

That's exactly what a new study published in GeroScience just did. Researchers from Boston University's School of Medicine, working with the New England Centenarian Study - the world's largest and longest-running study of people who live to 100 or older - analyzed the complete metabolomic profiles of the longest-lived participants.

Metabolomics is the comprehensive analysis of metabolites - the small molecules your body produces as a byproduct of every biochemical reaction - that together paint a detailed picture of how your metabolism is actually functioning at the molecular level.

In other words: what does 100-year-old blood actually look like, and what does that tell us?

The science breakdown:

Why does this matter? Because metabolomics is becoming one of the most actionable areas of longevity medicine. Unlike genetics (you can't change your genes), your metabolic profile can be shifted through lifestyle. And knowing what a 100-year-old's blood looks like gives researchers and clinicians a specific molecular target to measure against - not just a vague concept of "healthy aging."

The practical takeaway: the metabolic patterns associated with extreme longevity consistently show up in people who exercise regularly, maintain metabolic health, manage inflammation, and eat in ways that support mitochondrial function. What's new is the specific molecular fingerprint to track those efforts against. And increasingly, blood biomarker platforms can do exactly that - which makes this week's Check Your Stack section a natural companion to this story.

👉 ScienceDaily | Full study in GeroScience

It just surpassed a $1B valuation, joining private US companies like SpaceX and OpenAI. Unlike them, you can invest in EnergyX today. General Motors already has. Why? EnergyX’s tech can recover up to 3X more lithium than traditional methods. Now, they hold rights to ~13M tons of lithium across North and South America. Invest in EnergyX at $13/share by 7/16.

Invest in EnergyX

^{Energy Exploration Technologies, Inc. (“EnergyX”) has engaged Beehiiv to publish this communication in connection with EnergyX’s ongoing Regulation A offering. Beehiiv has been paid in cash and may receive additional compensation. Beehiiv and/or its affiliates do not currently hold securities of EnergyX.}

^{This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX’s offering materials. EnergyX’s Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.}

^{Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty.}

The Alzheimer's Association International Conference 2026 - AAIC - opens its doors today in London, running through July 15. It's the single largest annual gathering of Alzheimer's researchers, clinicians, and drug developers in the world. And this year's data package is unusually consequential. Here's why the industry is watching this week closely:

Lecanemab's most important data week since approval. Eisai is presenting 52 abstracts across its Alzheimer's portfolio at AAIC - the most comprehensive data package they've released in a single event. The centerpiece: today's session on the subcutaneous formulation of lecanemab (Leqembi). Lecanemab is currently administered by IV infusion at infusion centers - a significant barrier for patients who have to travel to specialized facilities regularly. A subcutaneous autoinjector version, which patients could self-administer at home, is under FDA Priority Review with a PDUFA decision date of August 24, 2026. Today's data on real-world patient experience and clinical outcomes with sub-Q dosing will shape how that application lands.

Three years of real-world data. On Tuesday, Eisai presents the LEADER study - a comprehensive multicenter retrospective study of lecanemab's performance three years post-approval in diverse US clinical settings, including results from at-home subcutaneous administration. This is the first time we see how the drug is actually performing outside clinical trials across a wide patient population.

The next generation: tau-targeting enters the picture. Eisai is also presenting Phase 2 data on etalanetug (E2814), an antibody targeting MTBR-tau - a different part of the Alzheimer's protein cascade than amyloid. The emerging strategy: lecanemab to clear amyloid, etalanetug to target tau simultaneously. If both pathways can be addressed together, the disease-modifying effect could be substantially stronger.

The market signal: if sub-Q approval comes through in August, lecanemab's addressable market expands significantly. Self-injection from home removes the infusion center barrier that has been one of the biggest limiting factors in real-world uptake. Watch August 24.

👉 Eisai AAIC 2026 announcement | AAIC 2026

For that you get a single blood draw covering 100+ biomarkers - hormones, thyroid, metabolic function, inflammation, cardiovascular markers, nutrients, liver, kidney, and immune health - plus a personalized action plan, and 24/7 access to a care team, and a supplement marketplace with members-only pricing.

Testing happens at 2,000+ labs across the US, or you can book a home visit. HSA and FSA eligible.

Results land in your dashboard within about a week, organized into 17 health scores, a biological age estimate, and a clear breakdown of what to do next. You can sync your wearables, upload old lab PDFs, and track your trends over time.

If you've been optimizing sleep, training, and nutrition but have never actually looked under the hood - this is the missing piece.

👉 Get Superpower - use code STAYIN20OFF for $20 off your first purchase

You know GLP-1 drugs as Ozempic and Wegovy. They were designed for type 2 diabetes and obesity. They work - particularly well. The cardiometabolic benefits are real, well-studied, and significant.

Now a growing corner of the longevity world is experimenting with something different: taking semaglutide at sub-therapeutic doses - far below the standard prescribing amounts - with the idea of accessing the anti-inflammatory and metabolic benefits without the weight-loss effects. Telehealth clinics are already marketing this directly to longevity-curious consumers. Some longevity physicians are prescribing it. And the debate is getting serious.

The case for GLP-1 microdosing:

The case against:

The useful framing: GLP-1s are genuinely exciting drugs with real biological mechanisms that may matter for aging. But the longevity field has a pattern of taking drugs that work well for one indication and trying to stretch them into a general anti-aging protocol before the evidence supports it. This might be the next metformin story - or it might be another supplement fad in prescription drug clothing.

Worth watching. Not yet worth dosing.

👉 The Weekly Brief

Earlier we talked about scientists having found a molecular fingerprint of extreme longevity in centenarian blood. This book asks the next logical question: can what you eat actually influence that fingerprint?

Dr. William Li is a physician and researcher who has spent his career studying angiogenesis - the process by which the body grows new blood vessels, which turns out to be central to everything from tumor growth to wound healing to healthy aging. His framework: the human body has five health defense systems (angiogenesis, stem cell regeneration, the microbiome, DNA protection, and immunity), and specific foods can activate or strengthen each one.

That's not a vague wellness claim. The angiogenesis research in particular is grounded in decades of work and has been published in major journals including Science and the New England Journal of Medicine. The book translates that research into something practical - specific foods, mechanisms, and patterns - without dumbing it down.

One of the most readable explanations of why diet affects aging biology at the cellular level.

👉 Get Eat to Beat Disease

How To Repair Knees 👇

Confirmed sponsorships are filling up ad slots fast. To promote your longevity / biohacking product to our niche audience, download the media kit and get in touch with Sebastian at [email protected]